Pathway Diligence Before the Check Clears

Hillman, Andrew Jonathan

doi:10.5281/zenodo.23352298

Pathway Diligence Before the Check Clears

Author: Andrew Jonathan Hillman (ORCID 0009-0001-5396-321X)
Published: September 28, 2026, Zenodo. Also published in The Hillman Letter.
DOI: 10.5281/zenodo.23352298 (all versions); this version 10.5281/zenodo.23352299
License: CC BY 4.0

Abstract

Presents an operator checklist for family-office diligence on regenerative medicine deals after the same surgical procedure exception has failed. Explains how registration, IND status, and BLA licensure differ as legal postures and what to pressure-test before capital moves. Not legal advice.

Exosome, stem cell and extracellular vesicle products discussed here are not approved by the FDA for any indication. This essay describes regulatory and public records. It does not describe an available treatment, and it is not legal advice.

Read the PDF on Zenodo Permanent DOI record Read on The Hillman Letter OpenAlex record

Indexed in OpenAlex under author A5139488776.

All publications · Andrew J. Hillman · LinkedIn · Book a meeting